These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6342861)

  • 1. The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus.
    Scobie IN; Kesson CM; Ratcliffe JG; Maccuish AC
    Clin Endocrinol (Oxf); 1983 Feb; 18(2):179-85. PubMed ID: 6342861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
    Rau H; Althoff PH; Schmidt K; Usadel KH
    Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
    Lamberts SW; Verleun T; Zuiderwijk JM; Oosterom R
    Acta Endocrinol (Copenh); 1987 Jun; 115(2):196-202. PubMed ID: 2885995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep.
    Clarenbach P; Del Pozo E; Brownell J; Heredia E; Spiegel R; Cramer H
    Brain Res; 1980 Dec; 202(2):357-63. PubMed ID: 7437907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CV 205-502 in acromegaly.
    Chiodini PG; Attanasio R; Cozzi R; Dallabonzana D; Oppizzi G; Orlandi P; Strada S; Liuzzi A
    Acta Endocrinol (Copenh); 1993 May; 128(5):389-93. PubMed ID: 8100375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bromocriptine on maturity onset diabetes.
    Barnett AH; Chapman C; Gailer K; Hayter CJ
    Postgrad Med J; 1980 Jan; 56(651):11-4. PubMed ID: 6992131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells.
    Johansen PW; Haug E; Gautvik KM
    Acta Endocrinol (Copenh); 1985 Oct; 110(2):200-6. PubMed ID: 4060970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone, insulin, and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.
    Harrower AD; Yap PL; Nairn IM; Walton HJ; Strong JA; Craig A
    Br Med J; 1977 Jul; 2(6080):156-9. PubMed ID: 577473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone and prolactin secretion by dispersed cell cultures of a normal human pituitary: effects of thyrotrophin releasing hormone, theophylline, somatostatin, and 2-bromo-alpha-ergocryptine.
    Adams EF; Brajkovich IE; Mashiter K
    Acta Endocrinol (Copenh); 1981 Nov; 98(3):345-51. PubMed ID: 6117169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments.
    Bigazzi M; Ronga R; Lancranjan I; Ferraro S; Branconi F; Buzzoni P; Martorana G; Scarselli GF; Del Pozo E
    J Clin Endocrinol Metab; 1979 Jan; 48(1):9-12. PubMed ID: 422709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No acute effect of pimozide on the plasma GH levels in acromegaly.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):461-8. PubMed ID: 6613492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly.
    Feek CM; Bevan JS; Taylor S; Brown NS; Baird JD
    Clin Endocrinol (Oxf); 1981 Nov; 15(5):473-8. PubMed ID: 7035013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytocidal effects of bromocriptine, somatostatin analog, and heat on growth hormone-secreting pituitary adenoma in vitro.
    Kawamoto K; Uozumi T; Sakoda K; Mukada K; Kurisu K; Yano T
    Cancer; 1992 Jun; 69(11):2688-96. PubMed ID: 1571899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
    Maccario M; Grottoli S; Procopio M; Oleandri SE; Barberis A; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1996 Apr; 19(4):219-23. PubMed ID: 8862501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone.
    del Pozo E; Schlüter K; Nüesch E; Rosenthaler J; Kerp L
    Eur J Clin Pharmacol; 1986; 29(5):615-8. PubMed ID: 3956565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of euglycemia and hyperglycemia on stimulated pituitary hormone release in insulin-dependent diabetics.
    Vierhapper H; Grubeck-Loebenstein B; Bratusch-Marrain P; Panzer S; Waldhäusl W
    J Clin Endocrinol Metab; 1981 Jun; 52(6):1230-4. PubMed ID: 6785297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.